News about "Sanofi"

State of Texas Sues Bristol-Myers Squibb, Sanofi Over Alleged Failure to Disclose Plavix Efficacy

McKool Smith and The Lanier Law Firm, along with Texas Attorney General Ken Paxton, have filed a lawsuit on behalf of the State of Texas against Bristol-Myers Squibb Company and several Sanofi entities, alleging the companies failed to disclose the efficacy and safety profile of the drug Plavix, which is used as a blood thinner.

Sanofi | 21/11/2025 | By Dineshwori

CHMP Recommends Sanofi's Tezeild for EU Approval in Stage 2 Type 1 Diabetes

The CHMP has backed EU approval for Sanofi’s Tezeild, supported by TN-10 study results showing the therapy can delay progression to stage 3 type 1 diabetes in patients with stage 2 disease. If authorised, Tezeild would become the first disease-modifying treatment for T1D in the EU.

Sanofi | 15/11/2025 | By Dineshwori |  177

Sanofi and Regeneron's Dupixent Meets Key Goals in Allergic Fungal Rhinosinusitis; FDA Grants Priority Review

Phase 3 results show Dupixent significantly improved nasal symptoms and sinus health in patients aged six and above with allergic fungal rhinosinusitis, supporting its FDA priority review.

Sanofi | 10/11/2025 | By Dineshwori |  113

Sanofi India Names Deepak Arora as MD Starting October 27, 2025

Approved by Sanofi India’s Board, the appointment places Deepak Arora in charge of steering the company’s strategic priorities and operations in line with its global vision.

Sanofi | 28/10/2025 | By Dineshwori |  113

Sanofi's Efdoralprin Alfa Meets Key Goals in Phase-II AATD Emphysema Study

Efdoralprin Alfa was previously granted fast track and Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA) for the treatment of AATD Emphysema. It is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

Sanofi | 27/10/2025 | By Dineshwori |  101

Sanofi Names Montpellier Global Hub for Autoimmune Disease Research

Sanofi, in partnership with the Immun4Cure University Hospital Institute in Montpellier, has launched a Translational Centre of Excellence focused on developing treatments for autoimmune and inflammatory diseases. The centre aims to place patients at the core of R&D, spanning early research through advanced clinical trials.

Sanofi | 16/10/2025 | By Dineshwori |  174

Sanofi and Partners Report Positive Phase 2 Results for AlphaMedix in Advanced GEP-NETs

AlphaMedix, which is developed by Orano Med and RadioMedix and now licensed to Sanofi, achieved all primary efficacy endpoints in the phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumours.

Sanofi | 08/10/2025 | By Dineshwori |  342

Novavax, Sanofi Deepen Partnership to Include Matrix-M in Pandemic Influenza Vaccine Programme

The expanded partnership allows Sanofi to use Novavax’s Matrix-M adjuvant in its pandemic influenza vaccine candidate programme.

Sanofi | 01/10/2025 | By Dineshwori |  184

US FDA Grants Fast Track Designation to AAV Gene Therapy by Sanofi

The US FDA has granted fast track designation to Sanofi’s SAR446268, an AAV gene therapy for juvenile and adult-onset myotonic dystrophy type 1 (DM1).

Sanofi | 23/09/2025 | By Dineshwori |  180

Sanofi Drug Earns Fast Track Status for Wet AMD in US

Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.

Sanofi | 11/09/2025 | By Dineshwori |  113